3rd Epigenetic–Targeted Drug Discovery & Development Summit
The 3rd Epigenetic – Targeted Drug Discovery & Development Summit pulls together world leaders in epigenetic research and development from groundbreaking academia, large pharma, non-profit organizations, and the bustling biotech industry.
70 Attendees | 5+ hours of Networking with Industry Peers
Two Interactive Pre-Conference Workshops | Exclusive Presentations from 17 Field Experts
Novel case studies showcasing multiple pharmacological interventions to epigenetic targets, from histone deacetylases (HDACs) and demethylases inhibitors, right through to CRISPR/Cas9 systems, epigenetic editing, and targeted protein degradation (TPD). Collaborative panels will debate multiple targeting strategies including specific loss and gain of function, synthetic lethality, along with combinatorial approaches and checkpoint inhibitors to overcome drug resistance.
This meeting aims to accelerate and enrich your epigenetic drug development pipeline by: